1270-PUB: Utilization Pattern of Dulaglutide in Five European Countries

Abstract

This descriptive drug utilization study was conducted using longitudinal health records between 2015 and 2017 from France, Germany, Spain, Sweden, and the UK to describe the frequency of dulaglutide use among populations of interest for which little data was available in initial registration clinical trials. Populations of interest included initiators with severe renal failure, hepatic disease, heart failure, and severe gastrointestinal (GI) disease; children and adolescents; elderly patients (≥75 years old); and pregnant and breast-feeding women. A total of 15,619 dulaglutide initiators were identified. All dulaglutide initiators in Germany and the UK, and majority of patients in other countries were diagnosed with type 2 diabetes, with most using dulaglutide as second-line therapy (Table). Two adolescent patients (15-17 years old) were identified. More than one-third were elderly (≥65 years old); those aged ≥75 years comprised 5-10% of dulaglutide initiators in all countries. Among women treated with dulaglutide, 11 were pregnant or breast-feeding at the time of dulaglutide initiation. Few to no patients had pre-existing severe renal failure. Frequency ranges of other conditions were: hepatic disease (0.7-17%), heart failure (1.5-11%), and severe GI disease (4.9-19%). This study showed that dulaglutide is generally being prescribed to the intended population according to the labelled indication in the five countries studied. Disclosure A. K. Ali: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company.